Levomilnacipran (Fetzima™) for the treatment of major depressive disorder
Levomilnacipran (Fetzima ™ ) was approved by the United States Food and Drug Administration (FDA) in July 2013 for the treatment of Major Depressive Disorder (MDD) in adults. Levomilnacipran is the (1S,2R) enantiomer of racemic milnacipran and represents one of the newest medications designed and ma...
Gespeichert in:
| Veröffentlicht in: | The mental health clinician 2014-01, Vol.4 (1), p.27-30 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 30 |
|---|---|
| container_issue | 1 |
| container_start_page | 27 |
| container_title | The mental health clinician |
| container_volume | 4 |
| creator | Ross, Clint |
| description | Levomilnacipran (Fetzima ™ ) was approved by the United States Food and Drug Administration (FDA) in July 2013 for the treatment of Major Depressive Disorder (MDD) in adults. Levomilnacipran is the (1S,2R) enantiomer of racemic milnacipran and represents one of the newest medications designed and marketed as an enantiomer of an already approved medication with hopes of improving efficacy and limiting side effects. This article reviews the evidence supporting the use of milnacipran for MDD, examines the clinical studies behind levomilnacipran's approval, and discusses practical considerations regarding the use of this new antidepressant medication. |
| doi_str_mv | 10.9740/mhc.n186963 |
| format | Article |
| fullrecord | <record><control><sourceid>crossref</sourceid><recordid>TN_cdi_crossref_primary_10_9740_mhc_n186963</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_9740_mhc_n186963</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1433-7229d34752a87402deefdf4c9b89fa090f6b6a4f0833b213fb0b91957761fa1b3</originalsourceid><addsrcrecordid>eNpNkMtKAzEYhYMoWGpXvkCWikz75zLJZCnFqnTAja6HZPKHTulcSIaCrn0SH80nccQuXJ3DWRw-PkKuGSyNlrBqd_WyY4UySpyRGWeqyIwGc_6vX5JFSnsA4MBkrsyMbEs89m1z6GzdDNF29GaD40fT2u_Pr1sa-kjHHdIxoh1b7EbaB9ra_TR7HCKm1ByR-ib10WO8IhfBHhIuTjknb5uH1_VTVr48Pq_vy6xmUohMc268kDrntpi4uUcMPsjauMIECwaCcsrKAIUQjjMRHDjDTK61YsEyJ-bk7u-3jn1KEUM1xIk4vlcMql8V1aSiOqkQP29VUwQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Levomilnacipran (Fetzima™) for the treatment of major depressive disorder</title><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Ross, Clint</creator><creatorcontrib>Ross, Clint</creatorcontrib><description>Levomilnacipran (Fetzima ™ ) was approved by the United States Food and Drug Administration (FDA) in July 2013 for the treatment of Major Depressive Disorder (MDD) in adults. Levomilnacipran is the (1S,2R) enantiomer of racemic milnacipran and represents one of the newest medications designed and marketed as an enantiomer of an already approved medication with hopes of improving efficacy and limiting side effects. This article reviews the evidence supporting the use of milnacipran for MDD, examines the clinical studies behind levomilnacipran's approval, and discusses practical considerations regarding the use of this new antidepressant medication.</description><identifier>ISSN: 2168-9709</identifier><identifier>EISSN: 2168-9709</identifier><identifier>DOI: 10.9740/mhc.n186963</identifier><language>eng</language><ispartof>The mental health clinician, 2014-01, Vol.4 (1), p.27-30</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,864,27924,27925</link.rule.ids></links><search><creatorcontrib>Ross, Clint</creatorcontrib><title>Levomilnacipran (Fetzima™) for the treatment of major depressive disorder</title><title>The mental health clinician</title><description>Levomilnacipran (Fetzima ™ ) was approved by the United States Food and Drug Administration (FDA) in July 2013 for the treatment of Major Depressive Disorder (MDD) in adults. Levomilnacipran is the (1S,2R) enantiomer of racemic milnacipran and represents one of the newest medications designed and marketed as an enantiomer of an already approved medication with hopes of improving efficacy and limiting side effects. This article reviews the evidence supporting the use of milnacipran for MDD, examines the clinical studies behind levomilnacipran's approval, and discusses practical considerations regarding the use of this new antidepressant medication.</description><issn>2168-9709</issn><issn>2168-9709</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><recordid>eNpNkMtKAzEYhYMoWGpXvkCWikz75zLJZCnFqnTAja6HZPKHTulcSIaCrn0SH80nccQuXJ3DWRw-PkKuGSyNlrBqd_WyY4UySpyRGWeqyIwGc_6vX5JFSnsA4MBkrsyMbEs89m1z6GzdDNF29GaD40fT2u_Pr1sa-kjHHdIxoh1b7EbaB9ra_TR7HCKm1ByR-ib10WO8IhfBHhIuTjknb5uH1_VTVr48Pq_vy6xmUohMc268kDrntpi4uUcMPsjauMIECwaCcsrKAIUQjjMRHDjDTK61YsEyJ-bk7u-3jn1KEUM1xIk4vlcMql8V1aSiOqkQP29VUwQ</recordid><startdate>201401</startdate><enddate>201401</enddate><creator>Ross, Clint</creator><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>201401</creationdate><title>Levomilnacipran (Fetzima™) for the treatment of major depressive disorder</title><author>Ross, Clint</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1433-7229d34752a87402deefdf4c9b89fa090f6b6a4f0833b213fb0b91957761fa1b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ross, Clint</creatorcontrib><collection>CrossRef</collection><jtitle>The mental health clinician</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ross, Clint</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Levomilnacipran (Fetzima™) for the treatment of major depressive disorder</atitle><jtitle>The mental health clinician</jtitle><date>2014-01</date><risdate>2014</risdate><volume>4</volume><issue>1</issue><spage>27</spage><epage>30</epage><pages>27-30</pages><issn>2168-9709</issn><eissn>2168-9709</eissn><abstract>Levomilnacipran (Fetzima ™ ) was approved by the United States Food and Drug Administration (FDA) in July 2013 for the treatment of Major Depressive Disorder (MDD) in adults. Levomilnacipran is the (1S,2R) enantiomer of racemic milnacipran and represents one of the newest medications designed and marketed as an enantiomer of an already approved medication with hopes of improving efficacy and limiting side effects. This article reviews the evidence supporting the use of milnacipran for MDD, examines the clinical studies behind levomilnacipran's approval, and discusses practical considerations regarding the use of this new antidepressant medication.</abstract><doi>10.9740/mhc.n186963</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2168-9709 |
| ispartof | The mental health clinician, 2014-01, Vol.4 (1), p.27-30 |
| issn | 2168-9709 2168-9709 |
| language | eng |
| recordid | cdi_crossref_primary_10_9740_mhc_n186963 |
| source | DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals |
| title | Levomilnacipran (Fetzima™) for the treatment of major depressive disorder |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T01%3A45%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-crossref&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Levomilnacipran%20(Fetzima%E2%84%A2)%20for%20the%20treatment%20of%20major%20depressive%20disorder&rft.jtitle=The%20mental%20health%20clinician&rft.au=Ross,%20Clint&rft.date=2014-01&rft.volume=4&rft.issue=1&rft.spage=27&rft.epage=30&rft.pages=27-30&rft.issn=2168-9709&rft.eissn=2168-9709&rft_id=info:doi/10.9740/mhc.n186963&rft_dat=%3Ccrossref%3E10_9740_mhc_n186963%3C/crossref%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |